FDA authorizes 3rd COVID vaccine dose for immunocompromised individuals

By The Science Advisory Board staff writers

August 13, 2021 -- The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines.

The authorizations now allow for the use of an additional vaccine dose in certain immunocompromised individuals, specifically solid organ transplant recipients or those who have been diagnosed with conditions that place them at an equivalent level of immunocompromise.

Other fully vaccinated individuals currently do not need an additional vaccine dose.

The FDA evaluated information on a third dose of the vaccines in individuals with compromised immune systems and determined that a third dose may increase protection. The administration said these patients should be counseled to maintain physical precautions to help prevent COVID-19.

Close contacts of immunocompromised individuals should get vaccinated to increase protection for this population, according to a statement by the FDA. The agency also recommends that immunocompromised individuals discuss monoclonal antibody treatment options with their healthcare provider should they contract or be exposed to COVID-19.

FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab...
Moderna files U.S. EUA for COVID-19 vaccine in adolescents
Moderna announced it has requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its COVID-19 vaccine in adolescents.
COVID-19 therapies could come from existing drugs
At least four drugs that have already been approved by the U.S. Food and Drug Administration may be effective as COVID-19 therapies, according to a study...
Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...
FDA issues EUA for GSK-Vir COVID-19 mAb treatment
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab...

Copyright © 2021 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter